ReviewPLoS neglected tropical diseases2014
The mycetoma knowledge gap: identification of research priorities.
Review in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Mycetoma (Madura Foot) in Israel: Recent Cases and a Systematic Review of the Literature.The American journal of tropical medicine and hygiene · 2017Pooled it
- Environmental and structural risk factors for mycetoma in the White Nile State, Sudan: an ethnographic study.International journal for equity in health · 2026Article
- Single-cell RNA sequencing unravels T cell exhaustion underlying the chronicity of chromoblastomycosis.Frontiers in immunology · 2026Article
- Clinical presentation, etiology, and treatment outcomes of mycetoma: A 25-year retrospective study in Southern Thailand.PLoS neglected tropical diseases · 2026Article
- The contribution of mycetoma grains to suboptimal disease management.Nature communications · 2025Review
- Advanced eumycetoma with intracranial extension in three Sudanese patients: a case series and review of the literature.Journal of medical case reports · 2025Review
- Eumycetoma: pathogenesis, current treatments, and the search for new drugs.Applied microbiology and biotechnology · 2025Review
- Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin.International journal of molecular sciences · 2025Review
- Epidemiology, risk factors, and awareness of mycetoma among residents in Eastern Sinnar locality, Sudan, 2021.Journal of global health · 2025Article
- Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.International journal of molecular sciences · 2025Article
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Review
- Environmental detection of eumycetoma pathogens using multiplex real-time PCR for soil DNA in Sennar State, Sudan.Tropical medicine and health · 2023Article
- The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.Medical mycology · 2023Article
- Neurological manifestations of mycetoma: a cross-sectional community-based study.Annals of medicine and surgery (2012) · 2023Article
- A scoping review of mycetoma profile in Egypt: revisiting the global endemicity map.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2023Article
- Genetic variability of the 16S rRNA gene of Nocardia brasiliensis, the most common causative agent of actinomycetoma in Latin America and the Caribbean.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Encapsulated eumycetoma caused byMedical mycology case reports · 2022Article
- Epidemiologic Aspects of Mycetoma in Africa.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycetoma is a tropical disease which is caused by a taxonomically diverse range of actinomycetes (actinomycetoma) and fungi (eumycetoma). The disease was only recently listed by the World Health Organization (WHO) as a neglected tropical disease (NTD). This recognition is the direct result of a meeting held in Geneva on February 1, 2013, in which experts on the disease from around the world met to identify the key research priorities needed to combat mycetoma. The areas that need to be addressed are highlighted here. The initial priority is to establish the incidence and prevalence of the disease in regions where mycetoma is endemic, prior to determining the primary reservoirs of the predominant causal agents and their mode of transmission to susceptible individuals in order to establish novel interventions that will reduce the impact of the disease on individuals, families, and communities. Critically, economical, reliable, and effective methods are required to achieve early diagnosis of infections and consequential improved therapeutic outcomes. Molecular techniques and serological assays were considered the most promising in the development of novel diagnostic tools to be used in endemic settings. Improved strategies for treating eumycetoma and actinomycetoma are also considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.